From Wikipedia, the free encyclopedia
Jump to: navigation, search
Systematic (IUPAC) name
Clinical data
AHFS/Drugs.com International Drug Names
Legal status
CAS number 25301-02-4 YesY
ATC code R05CA01
PubChem CID 71388
DrugBank DB06439
ChemSpider 11052515 N
KEGG D03261 N
Chemical data
Formula (C15H21O(C2H4O)m)n
Molecular mass variable
 N (what is this?)  (verify)

Tyloxapol is a nonionic liquid polymer of the alkyl aryl polyether alcohol type. It is used as a surfactant to aid liquefaction and removal of mucopurulent[citation needed] (containing mucus and pus) bronchopulmonary secretions,[1][2] administered by inhalation through a nebulizer[3] or with a stream of oxygen.

With intraperitoneal injection, tyloxapol also blocks plasma lipolytic activity, and thus the breakdown of triglyceride-rich lipoproteins. This mechanism is used to induce experimental hyperlipidemia in animals.[4]


  1. ^ Sehgal, S. S.; Ewing, C. K.; Richards, T.; Taeusch, H. W. (1994). "Modified bovine surfactant (Survanta) versus a protein-free surfactant (Exosurf) in the treatment of respiratory distress syndrome in preterm infants: A pilot study". Journal of the National Medical Association 86 (1): 46–52. PMC 2607653. PMID 8151722.  edit
  2. ^ Rubin, B. K.; Ramirez, O.; King, M. (1992). "Mucus rheology and transport in neonatal respiratory distress syndrome and the effect of surfactant therapy". Chest 101 (4): 1080–1085. doi:10.1378/chest.101.4.1080. PMID 1555424.  edit
  3. ^ Drugs.com: Tyloxapol definition
  4. ^ Kourounakis, A. P.; Victoratos, P.; Peroulis, N.; Stefanou, N.; Yiangou, M.; Hadjipetrou, L.; Kourounakis, P. N. (2002). "Experimental hyperlipidemia and the effect of NSAIDs". Experimental and molecular pathology 73 (2): 135–138. doi:10.1006/exmp.2002.2449. PMID 12231215.  edit